$VVOS and $CELV just announced the launch of its s
Post# of 98125
This is the main product $VVOS will successfully market to people that are initially getting tested for sleep apnea. It is the perfect complimentary product for GLP signaling weight loss drugs.
The sleep apnea patients all suffer from massive imbalance of oxidative stress.
This product should tack on additional .50 cent EPS for $VVOS in 2025 and well over $1.00 added EPS in 2026.. $VVOS share price heading significantly higher.
Link:
https://finance.yahoo.com/news/groundbreaking...00564.html
NOTE: $VVOS has NOT PRed this terrific partnership yet.